We have located links that may give you full text access.
CLINICAL TRIAL
COMPARATIVE STUDY
JOURNAL ARTICLE
RANDOMIZED CONTROLLED TRIAL
Randomized, prospective trial of direct current versus bipolar electrocoagulation for bleeding internal hemorrhoids.
Gastrointestinal Endoscopy 1993 November
Fifty patients with bleeding internal hemorrhoids unresponsive to 6 weeks of standard medical therapy were randomly assigned to receive treatment with direct current or bipolar electrocoagulation. Treatment groups were similar in bleeding severity and internal hemorrhoid grade. Treatment sessions were significantly longer for direct current electrocoagulation (8.8 +/- 0.2 minutes) than for bipolar electrocoagulation (0.1 +/- 0.03 minutes) (p < 0.001). When compared to the bipolar electrocoagulation group, direct current electrocoagulation patients had more procedural pain that terminated therapy (5 of 25 patients [20%] versus 0 of 25 [0%], for a difference of 20% [95% confidence interval, 4% to 36%]; p = 0.05) and prolonged pain after the procedure (4 of 25 patients [16%] versus 1 of 25 [4%], for a difference of 12% [95% confidence interval, -4% to 28%]; p = 0.35). However, more post-treatment rectal ulcerations were seen in the bipolar electrocoagulation-treated group (6 of 25 patients [24%] versus 1 of 25 [4%], for a difference of 20% [95% confidence interval, 2% to 38%]; p = 0.10). Treatment groups did not differ in number of treatment sessions or months of follow-up. The rates of success, defined as obliteration of the hemorrhoids or cessation of bleeding with reduction of the hemorrhoids to grade 1 or less, for the direct current electrocoagulation and the bipolar electrocoagulation groups were 88% and 92%, respectively. Failures in the direct current electrocoagulation group were uncontrollable bleeding (n = 1) and refusal to continue therapy because of pain (n = 2).(ABSTRACT TRUNCATED AT 250 WORDS)
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app